About PhenoVista
PhenoVista is a Healthcare company based in San Diego (United States) founded in 2014, and was acquired by InSphero in May 2026. A CRO that provides phenotypic assay development and screening services. PhenoVista has raised $3 million across 4 funding rounds from investors including Fujifilm, InSphero and HHS. PhenoVista offers products and services including Custom Services, Ready-2-Go Assays, Cell Painting & Screening, and Imaging & Analysis. Its focus areas include Biopharma Outsourcing, CRO, Preclinical Studies and Diversified. Its legal entity is PHENOVISTA BIOSCIENCES. Its competitors include Reaction Biology and Quantumcyte; 1 of its 2 listed competitors has raised funding.
Company details
PhenoVista was founded in 2014 and is based in San Diego, United States. Operations are centered in the biotechnology sector as a contract research organization. Services encompass phenotypic assay development and high-throughput screening, with emphasis on functional neuronal assays utilizing iPS-derived neurons, embryonic stem cell differentiation, human inflammation models, and myotube formation processes. These capabilities support drug discovery efforts in neuroscience and related fields.
Products & Services of PhenoVista
PhenoVista offers a comprehensive portfolio of products and services, including Custom Services, Ready-2-Go Assays, Cell Painting & Screening, and Imaging & Analysis.
Tailored assays for specific drug discovery needs
Off-the-shelf solutions for immediate research use
Techniques for visualizing and screening cellular responses
Advanced imaging to provide quantitative biological insights
Apps and channels of PhenoVista
its YouTube channel PhenoVista Biosciences has 16 subscribers and 7 videos.
Videos from PhenoVista
The most watched videos on PhenoVista's YouTube channel, PhenoVista Biosciences (16 subscribers). Click a video to play it here.
More on PhenoVista Biosciences.
Funding Insights of PhenoVista
PhenoVista has successfully raised a total of $3M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $3 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $3M
- Total Rounds 4
- Last Round Seed — $3M
- First Round $1.57M
(Sep 2017)
- Investors Count 2
All 4 funding rounds of PhenoVista with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in PhenoVista
PhenoVista has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Fujifilm, InSphero and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are invested in by the venture capital firm. | 1934 | fujifilm.com | Minato, Japan | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Cell-based assays and 3D microtissues for drug screening are developed. | 2009 | insphero.com | Schlieren, Switzerland |
Investor details for PhenoVista
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of PhenoVista
8 people are tracked at PhenoVista (3 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Marshall Peterman | Associate Director Of Scientific Operations | Leadership |
Chris Koehler | Director Of Scientific Operations | Leadership |
James G. Evans | CEO | Leadership |
Anthony Essex | CSO | Team |
Reese Prentice | Associate Scientist I | Team |
Nimesha Tadepalle | Scientist III | Team |
Aisling Ogilvie | Senior Business Development Representative | Team |
Tristin Raymond | Senior Research Associate | Team |
Complete people profiles for PhenoVista
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of PhenoVista
4 dated milestones of PhenoVista across 12 years, from founding to its latest funding, stage changes and deals.
- Founded PhenoVista is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Seed, of $3.0M.
- Exit Acquired by InSphero.
Competitors of PhenoVista
PhenoVista has 2 listed competitors in our database, 1 of them funded. They include Reaction Biology and Quantumcyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| reactionbiology.com | 2001 | United States | 77 | In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling | ||
| quantumcyte.com | 2013 | Sunnyvale, United States | $1.3M | Drug assay systems for cancer treatment are developed and provided. |
Detailed competitors of PhenoVista
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of PhenoVista
The website of PhenoVista (phenovista.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 10% vs previous month
Websites whose visitors overlap most with PhenoVista. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| selvita.com | 100% | 22.5K | #1,046,335 | View details | |
validation.org | validation.org | 82% | #9,714,983 | – | |
| valasciences.com | 80% | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as PhenoVista (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Phenovista
Complete news archive for PhenoVista
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PhenoVista
PhenoVista was founded in 2014 and raised its 1st funding round 3 years after it was founded.
PhenoVista is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
PhenoVista is a funded company, having raised a total of $3M across 4 funding rounds to date. The company's 1st funding round was a Grant of $1.57M, raised on Sep 2017.
PhenoVista was founded in 2014 and is based in San Diego, United States. Operations are centered in the biotechnology sector as a contract research organization. Services encompass phenotypic assay development and high-throughput screening, with emphasis on functional neuronal assays utilizing iPS-derived neurons, embryonic stem cell differentiation, human inflammation models, and myotube formation processes. These capabilities support drug discovery efforts in neuroscience and related fields.
PhenoVista's top competitors include Quantumcyte and Reaction Biology.
PhenoVista offers Custom Services, Ready-2-Go Assays, Cell Painting & Screening, and Imaging & Analysis.
PhenoVista operates through Phenovista Biosciences.
Yes. PhenoVista was acquired by InSphero in May 2026.